#Canada #Toronto #Drug Development #Hot Melt Extrusion #Poorly Soluble APIs

Hot Melt Extrusion: A Solution for Drug Development Challenges

In the ever-evolving field of pharmaceutical development, the challenge of formulating drugs with poorly soluble active pharmaceutical ingredients (APIs) is a pressing issue. Over 80% of research and development candidates face bioavailability hurdles due to inadequate solubility, hindering effective drug delivery. To address these challenges, Xtalks is hosting a comprehensive webinar that focuses on Hot Melt Extrusion (HME) as a leading technology for improving solubility and bioavailability in pharmaceutical formulations.

Understanding the Issues

Many APIs exhibit poor solubility, often leading to a substantial decline in their therapeutic effectiveness and bioavailability. Solutions like lipid-based systems and amorphous solid dispersions have been explored; however, HME presents a novel approach to combat these formulation challenges by transforming solid powders into molten polymers, allowing for the potential encapsulation of substances that would otherwise be insoluble.

Insights from Industry Experts

During the webinar, attendees will gain insights from distinguished speakers, including Dr. Klaus Pollinger, Group Director of Global Product Development at Aenova Group, and Dr. George Shlieout, Head of MST at Aenova Group. These industry leaders will share their expertise in pre-formulation, formulation development, process design, and commercial manufacturing scale-up. The dialogue aims at empowering participants with practical guidance on designing HME-based formulations and defining the critical process parameters to allow for swift and efficient product development.

The Webinar Experience

Set to take place live on September 17, 2025, at 9 AM EDT, this session will explore practical strategies through an engaging case study that illustrates the significant impact of HME on formulation and overall product development. Attendees will be equipped with the knowledge to make informed decisions regarding technology options available in their processes and how to set up HME processes efficiently.

Benefits of Attending

This webinar is not only beneficial for those involved in R&D for poorly soluble drugs; it also provides critical insights for pharmaceutical scientists and product managers seeking to stay ahead in the competitive landscape of drug development. By gaining firsthand knowledge from leading experts, attendees can better navigate the intricacies of HME technology and its application in solving drug solubility challenges.

Register today at Xtalks for the opportunity to enhance your understanding and application of HME in drug development. This is an invaluable chance to glean knowledge that could redefine your approach to overcoming formulation hurdles for poorly soluble APIs.

Conclusion

Hot Melt Extrusion is reshaping the landscape of pharmaceutical formulation, providing necessary solutions to address the challenges of poor solubility in drug development. Ensure that your innovative medicines effectively reach patients by leveraging advanced technologies discussed during this informative webinar. Don't miss the chance to learn from the best in the field and take your pharmaceutical expertise to the next level!